CTLA4 and glioblastoma: Use of multiple combinations of immunotherapies for targeting the over-expressive immunosuppression by PD-L1 (programmed cell death protein - ligand 1) and CTLA4 (cytotoxic T-lymphocyte-associated antigen 4) have effective potential in the suppression of glioblastoma [47].